FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883362011> ?p ?o ?g. }

• W2883362011 endingPage "1473.e6" @default.
• W2883362011 startingPage "1463" @default.
• W2883362011 abstract "Background & AimsDe novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step in this process. We evaluated the safety and efficacy of GS-0976, an inhibitor of acetyl-coenzyme A carboxylase in liver, in a phase 2 randomized placebo-controlled trial of patients with NASH.MethodsWe analyzed data from 126 patients with hepatic steatosis of at least 8%, based on the magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), and liver stiffness of at least 2.5 kPa, based on magnetic resonance elastography measurement or historical biopsy result consistent with NASH and F1–F3 fibrosis. Patients were randomly assigned (2:2:1) to groups given GS-0976 20 mg, GS-0976 5 mg, or placebo daily for 12 weeks, from August 8, 2016 through July 18, 2017. Measures of hepatic steatosis, stiffness, serum markers of fibrosis, and plasma metabolomics were evaluated. The primary aims were to confirm previous findings and evaluate the relation between dose and efficacy.ResultsA relative decrease of at least 30% from baseline in MRI-PDFF (PDFF response) occurred in 48% of patients given GS-0976 20 mg (P = .004 vs placebo), 23% given GS-0976 5 mg (P = .43 vs placebo), and 15% given placebo. Median relative decreases in MRI-PDFF were greater in patients given GS-0976 20 mg (decrease of 29%) than those given placebo (decrease of 8%; P = .002). Changes in magnetic resonance elastography-measured stiffness did not differ among groups, but a dose-dependent decrease in the fibrosis marker tissue inhibitor of metalloproteinase 1 was observed in patients given GS-0976 20 mg. Plasma levels of acylcarnitine species also decreased in patients with a PDFF response given GS-0976 20 mg. GS-0976 was safe, but median relative increases of 11% and 13% in serum levels of triglycerides were observed in patients given GS-0976.ConclusionsIn a randomized placebo-controlled trial of patients with NASH, we found 12-week administration of GS-0976 20 mg decreased hepatic steatosis, selected markers of fibrosis, and liver biochemistry. ClinicalTrials.gov ID NCT02856555. De novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step in this process. We evaluated the safety and efficacy of GS-0976, an inhibitor of acetyl-coenzyme A carboxylase in liver, in a phase 2 randomized placebo-controlled trial of patients with NASH. We analyzed data from 126 patients with hepatic steatosis of at least 8%, based on the magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), and liver stiffness of at least 2.5 kPa, based on magnetic resonance elastography measurement or historical biopsy result consistent with NASH and F1–F3 fibrosis. Patients were randomly assigned (2:2:1) to groups given GS-0976 20 mg, GS-0976 5 mg, or placebo daily for 12 weeks, from August 8, 2016 through July 18, 2017. Measures of hepatic steatosis, stiffness, serum markers of fibrosis, and plasma metabolomics were evaluated. The primary aims were to confirm previous findings and evaluate the relation between dose and efficacy. A relative decrease of at least 30% from baseline in MRI-PDFF (PDFF response) occurred in 48% of patients given GS-0976 20 mg (P = .004 vs placebo), 23% given GS-0976 5 mg (P = .43 vs placebo), and 15% given placebo. Median relative decreases in MRI-PDFF were greater in patients given GS-0976 20 mg (decrease of 29%) than those given placebo (decrease of 8%; P = .002). Changes in magnetic resonance elastography-measured stiffness did not differ among groups, but a dose-dependent decrease in the fibrosis marker tissue inhibitor of metalloproteinase 1 was observed in patients given GS-0976 20 mg. Plasma levels of acylcarnitine species also decreased in patients with a PDFF response given GS-0976 20 mg. GS-0976 was safe, but median relative increases of 11% and 13% in serum levels of triglycerides were observed in patients given GS-0976. In a randomized placebo-controlled trial of patients with NASH, we found 12-week administration of GS-0976 20 mg decreased hepatic steatosis, selected markers of fibrosis, and liver biochemistry. ClinicalTrials.gov ID NCT02856555." @default.
• W2883362011 created "2018-08-03" @default.
• W2883362011 creator A5009422918 @default.
• W2883362011 creator A5013219986 @default.
• W2883362011 creator A5027014361 @default.
• W2883362011 creator A5031221529 @default.
• W2883362011 creator A5038497969 @default.
• W2883362011 creator A5040945321 @default.
• W2883362011 creator A5043846829 @default.
• W2883362011 creator A5044576014 @default.
• W2883362011 creator A5052059601 @default.
• W2883362011 creator A5060169505 @default.
• W2883362011 creator A5061825110 @default.
• W2883362011 creator A5064449939 @default.
• W2883362011 creator A5068192104 @default.
• W2883362011 creator A5075322332 @default.
• W2883362011 creator A5079144123 @default.
• W2883362011 creator A5088683463 @default.
• W2883362011 creator A5089993955 @default.
• W2883362011 creator A5091625375 @default.
• W2883362011 date "2018-11-01" @default.
• W2883362011 modified "2023-10-16" @default.
• W2883362011 title "GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease" @default.
• W2883362011 cites W163303422 @default.
• W2883362011 cites W1980270094 @default.
• W2883362011 cites W1982126966 @default.
• W2883362011 cites W1985236262 @default.
• W2883362011 cites W1985592156 @default.
• W2883362011 cites W2003518626 @default.
• W2883362011 cites W2005875533 @default.
• W2883362011 cites W2007486805 @default.
• W2883362011 cites W2048613643 @default.
• W2883362011 cites W2054571656 @default.
• W2883362011 cites W2065034018 @default.
• W2883362011 cites W2067740038 @default.
• W2883362011 cites W2071030431 @default.
• W2883362011 cites W2077455531 @default.
• W2883362011 cites W2077688724 @default.
• W2883362011 cites W2107943478 @default.
• W2883362011 cites W2117827638 @default.
• W2883362011 cites W2137832556 @default.
• W2883362011 cites W2139351004 @default.
• W2883362011 cites W2139958402 @default.
• W2883362011 cites W2153738368 @default.
• W2883362011 cites W2154739921 @default.
• W2883362011 cites W2162051951 @default.
• W2883362011 cites W2162819835 @default.
• W2883362011 cites W2166321004 @default.
• W2883362011 cites W2298914518 @default.
• W2883362011 cites W2314336137 @default.
• W2883362011 cites W2462595066 @default.
• W2883362011 cites W2508708811 @default.
• W2883362011 cites W2524167689 @default.
• W2883362011 cites W2562949639 @default.
• W2883362011 cites W2611949588 @default.
• W2883362011 cites W2740884150 @default.
• W2883362011 cites W2744982526 @default.
• W2883362011 cites W2754550313 @default.
• W2883362011 cites W2761264021 @default.
• W2883362011 cites W2799863868 @default.
• W2883362011 cites W2803502682 @default.
• W2883362011 doi "https://doi.org/10.1053/j.gastro.2018.07.027" @default.
• W2883362011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6318218" @default.
• W2883362011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30059671" @default.
• W2883362011 hasPublicationYear "2018" @default.
• W2883362011 type Work @default.
• W2883362011 sameAs 2883362011 @default.
• W2883362011 citedByCount "218" @default.
• W2883362011 countsByYear W28833620112018 @default.
• W2883362011 countsByYear W28833620112019 @default.
• W2883362011 countsByYear W28833620112020 @default.
• W2883362011 countsByYear W28833620112021 @default.
• W2883362011 countsByYear W28833620112022 @default.
• W2883362011 countsByYear W28833620112023 @default.
• W2883362011 crossrefType "journal-article" @default.
• W2883362011 hasAuthorship W2883362011A5009422918 @default.
• W2883362011 hasAuthorship W2883362011A5013219986 @default.
• W2883362011 hasAuthorship W2883362011A5027014361 @default.
• W2883362011 hasAuthorship W2883362011A5031221529 @default.
• W2883362011 hasAuthorship W2883362011A5038497969 @default.
• W2883362011 hasAuthorship W2883362011A5040945321 @default.
• W2883362011 hasAuthorship W2883362011A5043846829 @default.
• W2883362011 hasAuthorship W2883362011A5044576014 @default.
• W2883362011 hasAuthorship W2883362011A5052059601 @default.
• W2883362011 hasAuthorship W2883362011A5060169505 @default.
• W2883362011 hasAuthorship W2883362011A5061825110 @default.
• W2883362011 hasAuthorship W2883362011A5064449939 @default.
• W2883362011 hasAuthorship W2883362011A5068192104 @default.
• W2883362011 hasAuthorship W2883362011A5075322332 @default.
• W2883362011 hasAuthorship W2883362011A5079144123 @default.
• W2883362011 hasAuthorship W2883362011A5088683463 @default.
• W2883362011 hasAuthorship W2883362011A5089993955 @default.
• W2883362011 hasAuthorship W2883362011A5091625375 @default.
• W2883362011 hasBestOaLocation W28833620111 @default.
• W2883362011 hasConcept C126322002 @default.
• W2883362011 hasConcept C126838900 @default.
• W2883362011 hasConcept C134018914 @default.
• W2883362011 hasConcept C142724271 @default.

• next